Now showing items 1-5 of 5

    • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 

      Bigner, DD; Boulton, ST; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, James Emmett II; ... (17 authors) (Br J Cancer, 2012-10-23)
      BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation ...
    • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 

      Bigner, DD; Herndon, James Emmett II; Kuan, Chien-Tsun; Lipp, Eric S; McLendon, Roger E; Pegram, CN; Rasheed, A; ... (11 authors) (BMC Cancer, 2010-09-01)
      BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and ...
    • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 

      Bigner, DD; Herndon, James Emmett II; Kuan, Chien-Tsun; Lipp, Eric S; McLendon, Roger E; Pegram, CN; Rasheed, A; ... (11 authors) (BMC Cancer, 2010-09-01)
      BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and ...
    • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 

      Bigner, DD; Carpenter, AB; Diplas, BH; Friedman, AH; Friedman, H; Greer, PK; He, J; ... (22 authors) (Oncotarget, 2014-03-30)
      Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which ...
    • Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. 

      Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, James Emmett II; Lipp, Eric S; Lou, E; ... (12 authors) (Cancer Med, 2013-04)
      Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed ...